71例男性乳腺癌患者临床与预后分析

刘东颖; 谢广茹; 陈明

Abstract

刘东颖,谢广茹,陈明.71例男性乳腺癌患者临床与预后分析[J].Chinese journal of Epidemiology,2013,34(2):187-190

71例男性乳腺癌患者临床与预后分析

Analysis on the elinical and prognostic features of 71 male patients with breast cancer

Received:November 19, 2012

DOI：10.3760/cma.j.issn.0254-6450.2013.02.019

KeyWord: 乳腺肿瘤男性激素受体人类表皮生长因子受体一2

English Key Word: Male breast neoplasia Hormone receptor Human epidermal growth factorreceptor-2

FundProject:

Author Name	Affiliation	E-mail
Liu Dongying	Department of Integrated Medicine, Tianjin Medical University Cancer Institute and Hospital, Key laboratory of Cancer Prevention and Therapy Tianjin300060,China
Xie Guangru	Department of Integrated Medicine, Tianjin Medical University Cancer Institute and Hospital, Key laboratory of Cancer Prevention and Therapy Tianjin300060,China
Chen Ming	Departrzcent of Internal Medicine,Tianjin Nankai Hospital	cmtjnk@sina.com

Hits: 3305

Download times: 1243

Abstract:

目的探讨男性乳腺癌(MBC)患者临床病理特征及其预后。方法回顾性分析天津医科大学附属肿瘤医院2002年3月至2012年3月71例MBC患者的临床病理及生存资料。结果MBC患者年龄43~84(M=62)岁，中位年龄大于同期女性乳腺癌(FBC)患者(t=6．355，P=0．000)，与同期FBC例数之比为o．42%(71：16 796)；MBC病理类型以浸润性导管癌(x²=29．875，P=0．000)、临床分期以>ⅢA(x²=13．377，P=0．037)多见。MBC患者雌激素受体阳性率明显高于FBC患者，而人类表皮生长因子受体-2(HER-2)阳性率明显低于FBC患者x²=3．741，P=0．048；x²=12．845，P-0．002)。单因素和多因素分析发现MBC患者预后比FBC患者差(P-0.004，P=0.046)。MBC患者的HER-2表达水平是影响其预后的重要因素(x²=4．219，P=0．040)。结论MBC与FBC的临床特征及预后均存在显著差异。HER一2阳性可能对MBC的预后及治疗有重要意义。

English Abstract:

Objective Male breast cancer(MBC)iS a rare disease,with clinical and prognostic features still controversial．The aim of this study was to discuss the clinical characteristies and prognosis of MBC．Methods Clinical data related to 7 l MBC patients was reviewed．Results The radio of MBC to female breast cancer(FBC)was 42：1 0 000．Age related to the diagnosis of MBC ranged from 43 to 84 years with the median age as 62 years old．older than the FBC patients(t=6．355．P=0．000)．The percentage ofinvasive ducal carcinoma in MBC patients was much higher than in FBC patients(X ²=29．875,P=0．000)．The positive rate of estrogen receptor(ER)was significantly higher than those in FBC patients and the positive rates of human epidermal growth factor receptor-2(HER-2)were less frequently(X²=3．741,P=0．048 and X²=12．845,P=0．002) seen．Data from the univariate and multivariate analysis showed that the 3-．5-and 10-year survival rates of MBC were 82．6%．74．O%and 47．4%respectively。significantly higher than those in FBC patients(P=0．004．P=0．046)．Patients with positive HER-2 showed worse prognosis than HER-2 negative patients in MBC patients(X²=4．219,P=0．040)．Conclusion There were significant clinic-pathologic and prognostic differences between FBC and MBC patients．The HER-2 positivity seemed to be an important factor for the prognosis and treatment of patients with MBC．

View Fulltext Html FullText View/Add Comment Download reader